Cholinergic anti-inflammatory pathway and COVID-19

Mehranfard, Danial and C. Speth, Robert (2022) Cholinergic anti-inflammatory pathway and COVID-19. BioImpacts.

[thumbnail of bi-12-171.pdf] Text
bi-12-171.pdf - Published Version

Download (1MB)

Abstract

The cholinergic anti-inflammatory pathway (CAP) first described by Wang et al, 2003 has contemporary interest arising from the COVID-19 pandemic. While tobacco smoking has been considered an aggravating factor in the severity of COVID-19 infections, it has been suggested by some that the nicotine derived from tobacco could lessen the severity of COVID-19 infections. This spotlight briefly describes the CAP and its potential role as a therapeutic target for the treatment of COVID-19 infections using vagus nerve stimulation or selective alpha7 nicotinic acetylcholine receptor agonists.

Item Type: Article
Subjects: West Bengal Archive > Medical Science
Depositing User: Unnamed user with email support@westbengalarchive.com
Date Deposited: 10 Apr 2023 06:40
Last Modified: 28 Aug 2024 13:43
URI: http://article.stmacademicwriting.com/id/eprint/377

Actions (login required)

View Item
View Item